Frequently Asked Questions
The global biopharmaceutical contract manufacturing market was valued at USD 8.8 Billion in 2022.
The biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 9.5% between 2023 and 2030, reaching USD 17.9 Billion in 2030.
Mammalian is the leading segment by service, holding over 30% share in value in 2022.
Upstream governs the global demand for biopharmaceutical contract manufacturing, holding a massive share of over 50% in 2022.
The biologics segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the biopharmaceutical contract manufacturing industry, with an over one-third share in 2022.
The top players include Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS Pharma, and AGC Biologics.
The major market drivers are increasing demand for biologics and personalized medicine, growth of the biosimilars market, and advancements in technology and manufacturing processes.
The major market restraints include stringent and evolving regulatory landscape and complex manufacturing processes and quality control requirements.
Growth of the biosimilars market, emerging and outsourcing trends, and increasing demand for personalized medicine and targeted therapies.